Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial

OBJECTIVE: Data on osteoarthritis patients from the PRECISION trial were used to evaluate the cost-effectiveness of celecoxib (100 mg twice daily) versus ibuprofen (600–800 mg three times daily) and naproxen (375–500 mg twice daily). The perspective was that of the United Arab Emirates (UAE) healthc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chirikov, Viktor V, Walker, Chris, Stephens, Jennifer M, Schepman, Patricia, Chambers, Richard, Bakir, Mahmoud, Poorman, Gregory W, Haider, Seema, Farghaly, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141397/
https://www.ncbi.nlm.nih.gov/pubmed/34040400
http://dx.doi.org/10.2147/CEOR.S280556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141397/
https://www.ncbi.nlm.nih.gov/pubmed/34040400
http://dx.doi.org/10.2147/CEOR.S280556

Ejemplares similares